← Back to Search

Biological

Autologous conditioned plasma for Osteoarthritis

Phase 2 & 3

Waitlist Available

Led By Adam Anz, MD

Research Sponsored by Andrews Research & Education Foundation

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline, 1 month, 3 months, 6 months, 12 months, 18 months, and 24 months post injections

Awards & highlights

Study Summary

This trial is testing whether adding hyaluronic acid to a platelet-rich plasma injection will improve the injection's efficacy in treating symptomatic knee osteoarthritis.

Eligible Conditions

Osteoarthritis

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline, 1 month, 3 months, 6 months, 12 months, 18 months, and 24 months post injections

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline, 1 month, 3 months, 6 months, 12 months, 18 months, and 24 months post injections

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 1 month, 3 months, 6 months, 12 months, 18 months, and 24 months post injections for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in International Knee Documentation Committee Subjective Knee Evaluation Form

Change in Knee Injury and Osteoarthritis Outcome Score

Change in Western Ontario and McMaster University's Osteoarthritis Index (WOMAC)

Side effects data

From undefined Phase 3 trial • 332 Patients • NCT01240382

Eye irritation

Gastrointestinal bleeding

100%

80%

60%

40%

20%

Study treatment Arm

0.1% HA

3% DE-089

Trial Design

2Treatment groups

Experimental Treatment

Group I: Autologous conditioned plasma with hyaluronic acid groupExperimental Treatment1 Intervention

Participants in this group will receive a two-injection series of autologous conditioned plasma and hyaluronic acid (Hymovis, Fidia Pharmaceuticals) and a third injection on the third week of autologous conditioned plasma.

Group II: Autologous conditioned plasma groupExperimental Treatment1 Intervention

Participants in this group will receive a three-injection series of autologous conditioned plasma over the course of 3 consecutive weeks.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Autologous conditioned plasma

2019

Completed Phase 3

~190

Hyaluronan

2014

Completed Phase 4

~220

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Andrews Research & Education FoundationLead Sponsor

18 Previous Clinical Trials

819 Total Patients Enrolled

3 Trials studying Osteoarthritis

204 Patients Enrolled for Osteoarthritis

Adam Anz, MDPrincipal InvestigatorAndrews Institute

7 Previous Clinical Trials

310 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any specific prerequisites for potential participants of this experiment?

"This study is testing a new medication for patients with arthrosis that are between the ages of 30 and 80. They are looking for 60 participants in total."

Answered by AI

What other research has been conducted using Autologous conditioned plasma?

"Currently, there are 23 clinical trials studying Autologous conditioned plasma with 6 trials in Phase 3. While there are a few trials for Autologous conditioned plasma in Gulf Breeze, Florida, there are 37 locations running clinical trials for Autologous conditioned plasma."

Answered by AI

What are the inclusion criteria for this research project?

"This trial is not recruiting patients currently. The study was first posted on March 15th, 2019 and was last updated on August 4th, 2022. There are presently 724 other trials actively recruiting participants with arthrosis and 23 studies for Autologous conditioned plasma."

Answered by AI

How is Autologous conditioned plasma most often employed?

"Autologous conditioned plasma is a common treatment for a number of conditions, including but not limited to skin irritation, osteoarthritis, and dermabrasion."

Answered by AI

Is this experimental treatment only available to those under 25 years old?

"In order to meet the eligibility requirements for this clinical trial, applicants must fall between the ages of 30 to 80. There are 41 studies for patients under the age of 18 and 705 for patients over 65."

Answered by AI